An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

Part of paid clinical trials in Los Angeles, California.

Sponsor
Jonsson Comprehensive Cancer Center
Study ID
NCT05558904
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside — DRUG
    Given IV
  • Computed Tomography — PROCEDURE
    Undergo PET/CT
  • Laboratory Biomarker Analysis — OTHER
    Correlative studies
  • Positron Emission Tomography — PROCEDURE
    Undergo PET/CT

Study Details

The phase I/II trial assess the safety and efficacy of a new positron emission tomography (PET) test for early diagnosis of lung cancer. This study uses PET and Me-4FDG new glucose tracer (alpha-methyl-4-deoxy-4-\[(18)F\]fluoro-D-glucopyranoside) designed specifically to determine glucose update into cells in the body. PET is a non-invasive imaging method used to detect cancer in patient. Me4FDG is a radioactive glucose tracer used in PET to locate cells in the body taking up glucose by SGLT2. SLGT2 is a sodium glucose transport protein that accumulates glucose in some cells, e.g. kidney cells and tumors. This study may help researcher determine how effective PET with ME4FDG tracer works in detecting lung cancer.

Key Dates

Start date
Jan 19, 2023
Status verified
Sep 2025
Primary completion
Oct 1, 2026
Completion
Oct 1, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Diagnostic (Me-4FDG PET/CT)
    Patients receive Me-4FDG tracer IV and then undergo PET/CT over 15 minutes.

Primary Outcome Measure

Sensitivity of Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me-4FDG) positron-emission tomography (PET) scans [ Time Frame: within one month of surgery or biopsy ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Yesenia CalzadaLos AngelesCalifornia90095
Yesenia Calzada
[email protected]
424-946-5026
Claudio Scafoglio, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Yesenia Calzada· Los Angeles, CA

Related Studies